Amirali Talasaz Sells 1,310 Shares of Guardant Health Inc (NASDAQ:GH) Stock

Guardant Health Inc (NASDAQ:GH) COO Amirali Talasaz sold 1,310 shares of the stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $79.34, for a total transaction of $103,935.40. Following the sale, the chief operating officer now directly owns 72,321 shares of the company’s stock, valued at $5,737,948.14. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Amirali Talasaz also recently made the following trade(s):

  • On Friday, August 23rd, Amirali Talasaz sold 52,715 shares of Guardant Health stock. The shares were sold at an average price of $97.63, for a total transaction of $5,146,565.45.
  • On Monday, August 26th, Amirali Talasaz sold 618 shares of Guardant Health stock. The shares were sold at an average price of $93.52, for a total transaction of $57,795.36.

Shares of Guardant Health stock traded down $0.93 during midday trading on Friday, hitting $77.90. The company had a trading volume of 18,454 shares, compared to its average volume of 1,110,322. The stock has a market cap of $7.36 billion and a price-to-earnings ratio of -27.82. The company has a fifty day simple moving average of $68.80 and a 200 day simple moving average of $80.96. Guardant Health Inc has a 12-month low of $32.33 and a 12-month high of $112.21.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.14) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.39) by $0.25. The firm had revenue of $60.85 million during the quarter, compared to analyst estimates of $45.40 million. Guardant Health had a negative net margin of 40.99% and a negative return on equity of 11.70%. Guardant Health’s revenue was up 180.4% on a year-over-year basis. During the same period last year, the firm posted ($1.94) EPS. As a group, sell-side analysts anticipate that Guardant Health Inc will post -0.88 earnings per share for the current fiscal year.

Institutional investors have recently made changes to their positions in the stock. Morgan Stanley increased its holdings in Guardant Health by 151.8% in the 2nd quarter. Morgan Stanley now owns 4,814,366 shares of the company’s stock worth $415,624,000 after buying an additional 2,902,471 shares during the period. Vanguard Group Inc. increased its holdings in Guardant Health by 151.1% in the 2nd quarter. Vanguard Group Inc. now owns 2,893,820 shares of the company’s stock worth $249,824,000 after buying an additional 1,741,472 shares during the period. Jennison Associates LLC increased its holdings in Guardant Health by 301.7% in the 2nd quarter. Jennison Associates LLC now owns 2,753,535 shares of the company’s stock worth $237,713,000 after buying an additional 2,068,098 shares during the period. BlackRock Inc. increased its holdings in Guardant Health by 99.1% in the 2nd quarter. BlackRock Inc. now owns 2,255,809 shares of the company’s stock worth $194,745,000 after buying an additional 1,122,983 shares during the period. Finally, Price T Rowe Associates Inc. MD increased its holdings in Guardant Health by 23.6% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 1,749,430 shares of the company’s stock worth $151,028,000 after buying an additional 334,218 shares during the period. 82.06% of the stock is owned by hedge funds and other institutional investors.

GH has been the subject of several analyst reports. William Blair reissued an “outperform” rating on shares of Guardant Health in a research report on Friday, November 8th. Zacks Investment Research raised shares of Guardant Health from a “hold” rating to a “strong-buy” rating and set a $84.00 price objective for the company in a research report on Tuesday, November 12th. ValuEngine raised shares of Guardant Health from a “hold” rating to a “buy” rating in a research report on Friday, November 1st. JPMorgan Chase & Co. increased their price objective on shares of Guardant Health from $90.00 to $135.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th. Finally, Cowen set a $110.00 price objective on shares of Guardant Health and gave the company a “buy” rating in a research report on Wednesday, August 7th. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Guardant Health currently has a consensus rating of “Buy” and a consensus price target of $107.60.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications.

Recommended Story: What is the formula for calculating total return?

Insider Buying and Selling by Quarter for Guardant Health (NASDAQ:GH)

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.